ReviewFrontiers in medicine2025
Visual related quality of life after ICL V4c implantation in high myopia patients: a mini review.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High myopia (≥ - 6.00 D) poses significant challenges to visual function and quality of life, with implantable collamer lens (ICL) V4c implantation emerging as a pivotal treatment. This mini review synthesizes evidence on visual-related quality of life (VRQoL) following ICL V4c implantation, focusing on predictability, objective/subjective visual quality, and complications. ICL V4c demonstrates long-term safety and efficacy, with safety indices (postoperative best-corrected visual acuity/preoperative best-corrected visual acuity) of 1.01-1.10 and efficacy indices (postoperative uncorrected visual acuity/preoperative best-corrected visual acuity) exceeding 0.90 over 5 years. Objective metrics, including higher-order aberrations and intraocular scattering, remain stable or improve postoperatively, while subjective outcomes show high patient satisfaction despite common but mild issues like halos (90.1% incidence) and glare (66.7% incidence). Complications such as cataract (1.7-6.8% incidence), corneal endothelial cell loss (≤5.7% over 8 years), and ICL malposition are rare and often manageable. While axial length progression in super-high myopia requires monitoring, ICL V4c remains a robust option for enhancing VRQoL in high myopia patients. Future research should prioritize large-scale, long-term studies to validate outcomes and optimize surgical protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.